H.C. Wainwright raised the firm’s price target on Wave Life Sciences to $15 from $8 and keeps a Buy rating on the shares after the company selected the lead candidate aimed at silencing INHBE. The firm says a low single-digit subcutaneous dose was sufficient to see robust silencing indicating once in six months to yearly subcutaneous dose, which is an “encouraging start.” Given the “differentiated and encouraging” data set from the WVE-N531, the firm is incorporating WVE-N531 in the model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WVE:
- Wave Life Sciences Unveils New Corporate Presentation
- Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
- Wave Life Sciences announces upcoming presentations at MDA conference
- Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy